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Abstract 
Colorectal cancer (CRC) is the third major cause of cancer-related deaths in the United States in 
2020. Sex-related differences in CRC stage, prognosis, and metabolism have become 
increasingly popular in cancer research. Males have poorer survival for CRC, but females with 
right-sided colon cancer (RCC) have aberrant metabolism correlated with poor survival. Delay in 
knowing the condition of CRC in female patients would result in poor prognosis, which could be 
avoided by predicting prognostic outcomes. Random Survival Forest (RSF) is ideal for 
exploration and making predictions using metabolomics data with high dimension, strong 
collinearity, and heterogeneity, which CPH models could not efficiently address. In this 
retrospective study including 197 patients, we applied an RSF prediction method based on the 
backward selection algorithm in 5-year overall survival (OS) for 95 female CRC patients and 
validated its performance. We also investigated Cox proportional hazard models (CPH), lasso 
penalized Cox regression (Cox-Lasso), and Logistic Regression (LR) and compared their 
predictive performances. RSF using the backward selection algorithm showed the best 
performance with the C-index of the training and testing sets reaching 0.81(95% CI: 0.810-
0.813) and 0.78 (95% CI: 0.776-0.777) respectively and identified the five most predictive 
metabolites for female 5-year OS: glutathione, citrulline, phosphoenolpyruvate, lysoPC (16:0), 
and asparagine. Accordingly, the backward selection algorithm-based Random Survival Forest 
model using tumor tissue metabolic profile is promising for predicting 5-year OS for female 
CRC patients. The results could be easily interpreted and applied in preventive medicine and 
precision medicine, guiding clinicians in choosing targeted treatments by sex for better survival 
and avoiding unnecessary treatments.  
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List of Tables  
Table 1. Demographic Characteristics and Clinical Factors 
Characteristics No. of Patients 
5-Year Overall Survival (OS) 5-Year Recurrence-free Survival (RFS) 
Deaths, No. Rate, %a P* Cases, No. Rate, %a P* 
Age at diagnosis, y 




61-69 64 9 83.4 14 72.4 
70-79 81 15 78.7 12 81.4 
≥80 33 11 61.5 1 96.3 
Sex, n 




Female 95 14 83.2 13 84.0 
Chemotherapy, n 




No 131 19 83.7 15 85.0 
Clinical stage, n 
I 47 3 92.5 
0.001 
5 88.4 
0.091 II 86 13 82.4 11 82.0 
III 64 21 63.5 14 73.8 
Anatomic tumor location, n 




Right 98 20 75.6 11 85.3 
* P value of Log-rank test. 




Table 2. Results of fitting Cox model including sex, anatomic tumor location, clinical stage, and age on 5-year 
OS and RFS of patients with colorectal cancer (n = 197) 
Variables 
OS RFS 
HR 95% CI P HR 95% CI P 
Sex: male 2.05 1.04-4.05 0.039 1.25 (0.60, 2.59) 0.555 
Anatomic tumor location: RCC 0.84 0.42-1.68 0.623 0.72 (0.33, 1.56) 0.410 
Clinical stage: Late 4.17 2.11-8.24 <0.001 2.08 (1.01, 4.27) 0.047 








Table 3. Primary exploration of predictive performance using RSF for CRC prognosis. The MPER might 
slightly fluctuate due to randomness. MPER: Minimum prediction error rate. 
Outcome Population MPER Selected metabolites 
OS 
All patients (n = 197) 0.3085 
CDP-Ethanolamine, CMP, Dimethylsphingosine, Glutathione, 
disulfide, Hypoxanthine, Tyrosine 
Females (n = 95) 0.2100 Asparagine, Citrulline, Creatinine, DHAPorG3P, Glutathione  
Males (n = 102) 0.3407 Tyrosine, Uracil  
RFS 
All patients (n = 197) 0.3001 
Acetyl-lysine, Cytidine, Dimethylsphingosine, Glutathione 
disulfide, LysoPE (22:5), Palmitic acid, Xanthosine  
Females (n = 95) 0.3257 Glutathione, Glutathione disulfide  
Males (n = 102) 0.2356 Acetyl-lysine, Hypoxanthine, N1-Acetylspermine, Xanthosine  
 
Table 4. Characteristics of training and testing sets for CRC female patients (n = 95). 
Variables 
Training set Testing set 
P* 
(n = 58) (n = 37) 
Age (mean (SD))  70.98 (8.03) 72.11 (7.51) 0.490 
Chemotherapy, n     
Yes  21 14 
0.342 
No  37 23 
Clinical stage     
Early  38 22 
0.705 
Late  20 15 
Anatomic tumor location     
Left  28 17 
0.991 
Right  30 20 
Death     
Yes  9 5 
1.000 
No  49 32 
Follow-up months (mean (SD)) 48.43 (19.30) 44.79 (21.87) 0.560 








Table 5. Results of COX1 and COX2 model with determined factors on 5-year OS of female CRC patients 
based on the training set (n = 58). These two models were only for reference and comparison. They were invalid 
for interpretation or making predictions because they violated the proportional hazard assumption. Additionally, a 
small sample size with limited death events led to extremely high HRs. Thus, HRs were invalid and biased.  














glutathione disulfide 1.08 (0.48, 2.44) 0.852 Yes 
glycerol 3-phosphate 8.92 (1.17, 68.22) 0.035 Yes 
phosphoenolpyruvate 1.26 (0.60, 2.65) 0.544 Yes 
succinate 0.02 (0.00, 1.68) 0.084 No 
UDP-D-Glucose 1.23 (0.67, 2.25) 0.504 No 
Tumor location: RCC 1.09 (0.14, 8.54) 0.936 No 
Clinical stage: late 66.29 (3.51, 1251.58) 0.005 No 
Age 1.27 (1.08, 1.49) 0.004 Yes 
COX2 




glycerol 3-phosphate 9.43 (1.52, 58.55) 0.020 Yes 
succinate 0.08 (0.01, 0.71) 0.020 No 
Tumor location: RCC 1.60 (0.27, 9.55) 0.610 No 
Clinical stage: late 48.48 (4.87, 482.10) <0.001 No 
Age 1.25 (1.08, 1.44) 0.003 No 
 
Table 6. Variables with relative importance larger than 20% using RSF based on the training set (58 female 
patients). VIMP: variable importance. 
Variables VIMP Relative importance 
Citrulline 0.0228 100.00% 
Glutathione 0.0185 81.14% 
Asparagine 0.0117 51.45% 
LysoPC(16:0) 0.0104 45.60% 
Clinical Stage 0.0096 41.88% 
Creatinine 0.0079 34.62% 
Glucosamine 6-phosphate 0.0078 33.97% 
Age 0.0073 31.88% 
Glycerol 3-phosphate 0.0057 24.84% 
Taurine 0.0049 21.38% 






Table 7. Comparing predictive performance for models in both training set and testing set. COX1 model 
adopted statistically significant metabolites in individual analysis with clinical stage, tumor location, and age. COX2 
model included remaining variables generated from COX1 after forward stepwise selection procedure with 
minimum AIC. Cox-LASSO was a Cox regression model using all the variables with lasso penalty for feature 
selection. RSF1 was constructed by the stepwise RSF backward algorithm with a minimum prediction error rate. 
RSF2 used variables with VIMP > 0.005.  
Models 
C-index Estimates (95% CI) 
Training set (n = 58) Testing set (n = 37) 
COX1 0.9494 (0.9043-0.9945) 0.6000 (0.3656-0.8344) 
COX2 0.9448 (0.8938-0.9958) 0.6370 (0.4257-0.8483) 
Cox-LASSO 0.7056 (0.6903-0.7210) 0.6440 (0.6321-0.6558) 
RSF1 0.8117 (0.8104-0.8131) 0.7765 (0.7756-0.7773) 
RSF2 0.8469 (0.8462-0.8476) 0.6589 (0.6578-0.6600) 
















List of Figures  
 
Figure 1. Flowchart for the modeling process. RSF: random survival forest. LR: logistic regression. LASSO: least 
absolute shrinkage and selection operator. K-fold CV: k-fold cross-validation. C-index: concordance index. External 
validation: an important procedure to ensure sufficient robustness and generalizability using independent external 
data sets after the models are tested to be valid from internal validation (the current data set we have).  
                    
                    
             
          
             
                    
          
             
             
                  
                      
                  
     
              
          
          
             
              
            
              
                 
                                                                                            
      
 
      
 
  
      
 
    
     
              
      
         
         
           
        
         
           
        
            
              
   
             
               
            




† LysoPC: Lysophosphatidylcholine. 
Figure 2.  Sex differences in metabolites associated with CRC prognosis. Hazard ratios (HRs) for CRC by sex 
for individual metabolites (per 1 standard deviation, adjusted for anatomic location, clinical stage, and age 
(continuous)) (A) 5-year Overall survival (OS) and (B) 5-year Recurrence-free survival (RFS). A metabolite with 
HR <1 was associated with a protective effect on prognosis; metabolite with HR > 1 was associated with an adverse 
effect on prognosis. Metabolites with confidence intervals (CIs) marked with asterisks were significantly associated 
with the presented prognosis (Raw P values < 0.05). All the metabolites abundance (continuous) was log2 
transformed. The x-axes are log-scaled. Sex interaction P values < 0.05. 
         
          
          
                    
             
         
         
         
             
      
          
          
           
       
        
         
                      













           
       
         
         
                                
                     
          
         
            
      











Figure 3. Kaplan-Meier curve of training and testing sets. There was no statistically significant difference between 




Figure 4. Cox-LASSO modeling based on the training set (58 female patients). (A) 10-fold cross-validation 
curve using the training set as a function of the λ with upper and lower standard deviation bar. The optimum λ 
corresponded to the highest C-index. (B) a coefficient profile plot of the coefficient paths for a fitted Cox-LASSO 
model using the training set. At Log(λ)= -2.06, only coefficients of two variables were not penalized to 0: Clinical 




Log( ) = -2.06
Remaining ariables with 





Figure 5. Partial 5-year predicted survival for nine most predictive variables on survival in colorectal cancer 
data based on the training set (58 female patients). Values on the vertical axis represent predicted survival 
probability for a given predictor after adjusting for all other predictors (A-I). (J) Error rates of RSF for log-rank 
splitting rule. (K) Identified metabolites that are most predictive for 5-year OS among females by the minimal depth 
measurement. Metabolites were identified using the random survival forest backward algorithm. Metabolites with 
lower minimal depth values are more predictive regarding 5-year OS. Abbreviations LysoPC:  
Lysophosphatidylcholine. Dark dots in A-F represented survivors, and blue dots represented dead patients. 
    
    




Figure 6. Variable importance (VIMP) for variables with relative importance larger than 20% based on the 
training set (58 female patients) 
 
 
















Figure 7. Prediction performance for Logistic Regression (LR). ROC curve for training set (n = 58) (A) and 
testing set (n = 37) (B). ROC curve: receiver operating characteristic curve. AUC: Area under the ROC Curve. Pos 
Pred Value: Positive prediction value. Neg Pred Value: Negative prediction value. 
 
                  
                          
                   
                   
                       
                       
                    





Figure 8. Prediction performance over time for the four models in the testing set (n = 37). RSF1 model had the 
best predictive performance since month 20, followed by RSF2, COX2 and COX1. The dotted pink line indicates a 
C-index = 0.75 as an acceptance threshold for a valid predictive model. The dotted grey line indicates a C-index = 
0.5. Models with C-index < 0.5 were considered no better than predicting an outcome than random chance. RSF1 











According to CDC reports, colorectal cancer (CRC) is the third major cause of cancer-related 
deaths in the United States in 20201. CRC survival is not only related to the stage at diagnosis 
but is also strongly affected by the implementation of population-based screening that reduces 
colorectal cancer incidence and mortality2. Studies have shown that conventional risk factors 
included aging, family history of cancer, obesity, diets, alcohol consumption, smoking, low 
physical activity, and socioeconomic status3. Clinical and pathological variables such as 
inflammatory response, body mass index (BMI), tumor location and size, metastasis, lymph node 
metastasis, and pathological stage of tumors also greatly influence CRC survival and have been 
incorporated into prognosis prediction4. An emerging amount of new biomarker-based 
approaches have been applied in colorectal cancer screening programs due to less invasiveness, 
lower costs, and potentially higher detection accuracy, such as DNA methylation biomarker test 
using blood samples5 and tumor endothelial marker test6. In addition, stratified screening 
programs by risk factors including sex allow screening and preventive strategies to be targeted at 
those most likely to benefit while reducing the number of patients undergoing harmful or 
invasive tests, which unleash the potential to improve screening efficiency78.  
Sex-related differences in CRC prevalence, prognosis, clinical stage, and metabolism have 
become increasingly popular in cancer research91011. Males have poorer survival for CRC12. 
However, females have a higher prevalence of right-sided colon cancer (RCC)12, which was 
associated with and poor overall survival (OS)1314. Johnson Lab investigated untargeted 
metabolomics on tumor tissue, looked at the biological mechanisms, and found a positive 
association between aberrant metabolism in asparagine synthetase (ASNS) expression and poor 
survival15, which laid the foundation of this study. These findings suggest that sex plays a vital 
14 
 
role in CRC prognosis together with the influence of anatomic tumor location, clinical stage, and 
metabolism. Thus, it is promising to gain a complete view of how sex interacts with CRC 
prognosis by addressing the clinical problem from the perspectives of metabolomics that helps to 
reveal the biological background. Therefore, this study hypothesized that the untargeted 
metabolic profile of primary tumor tissue metabolites could reveal sex differences in the 
associations with CRC prognosis, and it could be used to predict CRC prognosis by sex.  
A couple of studies have built robust prediction models for CRC prognosis in recent years using 
clinical factors, biomarker data, and histopathological image data. Roshanaei et al. validated a 
random survival forest (RSF) model to identify important risk factors (metastasis to other organs, 
WBC count, disease stage, and the number of lymphomas) on mortality in CRC patients based 
on their demographic and clinical-related variables16. Xu et al. used logistic regression (LR) to 
predict the recurrence of stage IV CRC after tumor resection by considering time-to-event 
outcome as a binary outcome (whether recurrence occurred)17. Bychkov et al. developed an 
image-based deep learning approach to predict colorectal cancer outcomes based on images of 
tumor tissue samples that outperform an experienced human observer in extracting more 
prognostic information18. Kather et al. confirmed that convolutional neural networks (CNN) 
were able to assess the human tumor microenvironment and predict prognosis directly using 
histopathological images19. Biomarker-based prediction models such as the Circulating free 
DNA (cfDNA) -based prognostic prediction model based on LASSO-Cox methods achieved an 
excellent discriminating ability20.  
There are multiple statistics and machine learning approaches available to build models for 
prognosis prediction in clinical practice. In common, the Cox proportional hazards (CPH) 
models are used to evaluate the relationships between cancer prognosis and risk factors. 
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However, CPH is sometimes not suitable for analyzing data with high dimension, complex 
interactions between variables because it assumes that the outcome is a linear combination of 
covariates21. The proportional hazard assumption is often violated in some survival data22 , 
which could produce biased hazard ratios. To avoid the defects of CPH, other non-parametric 
models are more appropriate in this scenario. For metabolite data specifically, the exploratory 
analysis of high dimensional metabolomic data containing hundreds of highly correlated 
variables using regression approaches has unique statistical challenges related to multiple testing 
and multicollinearity, which had been a major difficulty in this study. Multiple studies have 
demonstrated that random survival forest (RSF) was a promising approach for identifying 
disease-associated variables in complex time to event data with a large number of highly 
correlated metabolites by utilizing a set of decision trees for prediction and ranking variables by 
their importance232425. With RSF backward elimination procedure, Dietrich et al. successfully 
extracted a series of informative metabolites for predicting type 2 diabetes mellitus (T2D) 5-year 
disease-free survival, some of which showed nonlinear relationships with prognosis, indicating 
the necessity of using RSF instead of CPH23. Likewise, our study also hypothesized that we 
could find predictive metabolites for CRC prognosis using advanced statistical methods. 
This study is a follow-up to the recent study at Johnson Lab, where we saw that high expression 
of genes encoding metabolic enzymes were associated with poorer survival in females with 
RCC15. We first looked at tumor tissue metabolites with sex differences in their associations with 
CRC prognosis (5-year overall survival and 5-year recurrence-free survival) considering 
anatomic tumor location, clinical stage, and age at diagnosis. Moreover, we examined the 
possibility of making predictions for CRC prognosis using tumor tissue metabolome considering 
sex difference, then identified predictive metabolites based on the RSF model for 5-year OS 
16 
 
among female patients. Finally, we built several predictive models, compared their predictive 
performances, and obtained the optimal one. 
Methods and materials  
Sample Collection and Metabolites Measurements 
Metabolites were extracted and analyzed by hydrophilic interaction chromatography mass 
spectrometry (HILIC-MS) and reverse phase liquid chromatography mass spectrometry (RPLC-
MS)-based metabolomics as previously described in an article by Cai et al.15. Only tumor tissue 
samples from RCCs and LCCs within stage I-III (n=197) were selected in this study. Finally, 
abundances of 91 metabolites were obtained. 
Statistical Analysis 
We included age, sex, anatomic tumor location, and clinical stage as covariates. Multivariable 
Cox proportional hazard regression models were constructed to evaluate the associations 
between prognosis with both individual metabolite abundance (1 SD differences on a log-scale) 
adjusted for covariates for all patients and for both sexes. Two prognostic outcomes were 
considered: 5-year overall survival (OS), 5-year recurrence-free survival (RFS). Due to the 
absence of death events among females at clinical stage I, we recoded the clinical stages I and II 
as “early stage”, and III as “late stage”. Patients with any types of chemotherapy prior to the 
follow-up were coded as having chemotherapy history. Survival analyses were conducted using 
package “survival” in R (version 4.0.4).  
17 
 
Random survival forest (RSF) 
An RSF is computed by a cluster of binary decision trees that have been frequently used to select 
the most important variables linked with time to event26. Minimal depth measurement is 
implemented to assess how informative a variable is regarding the time until event23. Harrell’s 
concordance index (C-index) is equal to 1- prediction error rate, which is commonly applied to 
evaluate the predictability of a model. Random survival forest models were trained using the 
“RandomForestSRC” R package. The RSF parameter number of trees and number of node splits 
were fixed at 1000 and 10 initially. We applied a random survival forest backward selection 
algorithm for variable selection to detect the most predictive and informative metabolites while 
forcing covariates into our models23, which finally automatically chose the set of metabolites 
producing the lowest prediction error rate. We used raw abundance in RSF modeling. 
LASSO-based CPH 
Regression with LASSO (least absolute shrinkage and selection operator) penalty is a commonly 
used method for variable selection in a high‐dimensional data analysis that produces results 
depend on the shrinkage parameter λ27. The R package “glmnet” was applied to Cox-LASSO 
modeling based on 10-fold cross-validation. 
Logistic Regression (LR) 
Logistic regression (LR) can predict the probability of occurrence of an event by fitting data to a 
sigmoidal S-shaped logistic curve28. Unlike survival models, LR dropped the time information 
and coded the event within a certain length of time as a binary variable (e.g., survival during the 




We ran RSF based on the backward selection algorithm for all patients and by sex for 5-year OS 
and RFS and then calculated minimum prediction error rates (MPER) for these six models that 
were forced to include clinical stage, age, anatomic tumor location, chemotherapy as covariates. 
MPER lower than 25% was considered as a standard indicating potential good predictive 
ability16, and we only further investigate models with MPER < 25% in our study. 
The whole modeling process could be summarized in Figure 1. To obtain a model with high 
generalizability, it is essential to split the data set into a training set and a testing set. The training 
procedure was conducted using an “inner” training set and validation set if we adopted the k-fold 
cross-validation technique for parameter tuning based on the machine learning algorithm of our 
choice. After multiple training cycles, we achieved a model with high fitting performance for the 
“outer” training set with 60% of the samples. If the performance was poor, we considered it as 
underfitting, and we would not proceed with further testing on the testing set. In this study, we 
aimed to build models with C-index at least over 0.75 (equal to prediction error rate < 0.25) in 
the training set (outer) that represented a promising potential of good predictive ability and then 
to test them in the testing set. If the C-index for the fitted model on the testing set is high (> 
0.75), the model is robust and generalizable and would be considered for external validation 
using data from other independent cohorts. Otherwise, if the predictive accuracy is not high 
enough, more valuable information should be collected and analyzed in future modeling for 
improvement, and combination with other screening, testing approaches would be necessary as a 






Baseline characteristics of 197 CRC cases (102 males and 95 females), including 5-year overall 
survival (OS) and 5-year recurrence-free survival (RFS), are shown in Table 1. In the cohort, 37 
total deaths and 30 recurrences were documented. The median follow-up time since the date of 
surgery for primary tumor was 74.8 months (range, 0.1-169.2 months). Older age at which the 
surgery was performed, having chemotherapy history, and advanced clinical stage were inversely 
related to OS survival rate. For each subgroup by anatomic tumor location and clinical stage, the 
demographic characteristics are displayed in Supplementary Table 1. Prognosis among different 
subgroups is shown in Supplementary Table 2. Among these variables, chemotherapy history 
was significantly associated with clinical stage for all patients (Wilcoxon rank-sum test P value < 
0.001), and the treatment effects of chemotherapy on prognosis counteracted the harmful effects 
of being late stages, which would make models hard to interpret. Thus, we believed that clinical 
stage provided enough information, and we did not include chemotherapy history as a covariate 
in the Cox Proportion Hazard (CPH). But we used both variables in other models using machine 
learning algorithms that could carry feature selection automatically and produce interpretable 
results. 
Cox proportional hazard regression (CPH) analysis  
In Table 2, sex was significantly associated with 5-year OS adjusted for anatomic tumor location, 
clinical stage, age. We then examined the sex differences in the associations between OS and 
metabolome and whether it was necessary to build different models by sex for prognosis 
20 
 
prediction. Sex seemed to be independently associated with RFS but still conducted the same 
analysis for RFS to see if any metabolites had sex heterogeneity in the associations with RFS. 
We first analyzed the relationships between the abundance of 91 metabolites and OS. 
Multivariate Cox proportional hazard (CPH) models estimated associations between 91 tumor 
tissue metabolites and CRC prognosis individually by sex with 1 SD differences (log-metabolite 
scale), adjusted for anatomic location, clinical stage, and age: 18 metabolites were significantly 
associated with OS (Supplementary Table 3) for either female or male patients (Supplementary 
Table 4). Twenty-five metabolites had statistically significant correlations with RFS for either 
females or males (Supplementary Table 4). For both supplementary tables 3 and 4, the P values 
were raw values before FDR adjustment. Only carnitine and hypoxanthine remained significantly 
associated with RFS for males after FDR adjustment. Fig. 2 summarizes metabolites whose 
associations with CRC prognosis differed by sex (interaction P values < 0.05).  
Adenosine, asparagine, citrulline, glycerol 3-phosphate, LysoPC (16:0) (lysophosphatidylcholine 
(16:0)), ornithine, succinate, threonine, UDP-D-Glucose, uracil, and xanthosine were found to 
have significant sex differences in their associations with CRC OS (Supplementary Table 3, Fig. 
2A). Among these 11 metabolites, succinate was associated with better OS for females 
(HROS=0.34 per SD, 95% CI: 0.12-0.96, P = 0.042), while it was associated with poorer overall 
survival for males (HROS=1.77 per SD, 95% CI: 1.21-2.58, P = 0.003) (Fig. 2A). 
Argininosuccinic acid, asparagine, creatinine, hypoxanthine, and serine were found to have 
significant but opposite associations with RFS between female and male patients (Supplementary 
Table 4, Fig. 2B). These metabolites were all significantly associated with RFS in males but 
were not associated with RFS in females. Interestingly, asparagine was observed to have sex 
differences for both OS and RFS (Fig. 2). Asparagine was significantly associated with better 
21 
 
CRC prognosis in male patients (both OS and RFS): HROS=0.72 per SD, 95% CI: 0.55-0.96, P = 
0.025; HRRFS=0.74 per SD, 95% CI: 0.56-0.98, P = 0.039, but there were no significant trends in 
female patients (interaction POS = 0.029, interaction PRFS = 0.009) (Supplementary Table 3, 4). 
None of the results in Fig. 2 violated the proportional hazards assumption. 
Multivariate CPH analysis that includes all metabolites with clinical variables was inappropriate 
because of strong collinearity and divergent results, given relatively small sample size and high 
dimension with around 100 variables. Thus, we hoped to reduce dimension by Principal 
Component Analysis (PCA). We tried to implement CPH analyses combined with PCA, but 
there was no statistically significant result for OS among female CRC patients (Supplementary 
Fig. 1, Supplementary Table 5, Supplementary Table 6). Thus, we sought other methods to 
identify predictive metabolites.  
Predictive modeling 
Primary exploration of the possibility to predict CRC prognosis using tumor 
tissue untargeted metabolic profile 
The identified sex interactions indicated potential sex heterogeneity. Thus, we conducted 
predictive modeling taking sex differences into account. We found that CPH models that 
included all the metabolites to select features could not converge for all patients or both sexes, 
even with stepwise selection methods. So, we turned to the Random Survival Forest algorithm 
(RSF) to handle high dimensional data and collinearity problems without having to consider the 
proportional hazard assumption. We ran RSF based on the backward selection algorithm for all 
patients and by sex for 5-year OS and RFS and then calculated prediction error rates (PER) of 
the model with selected variables together with clinical stage, age, anatomic tumor location, 
chemotherapy as covariates. We further investigated models with minimum PER lower than 
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25%, which was considered as a standard indicating potential good predictive ability in our 
study. The selected metabolites were different by sex. 
For example, the minimum prediction error rate for all patients was 0.3085 (Table 3). Thus, it 
was not good to predict OS for all patients using our metabolomic profile based on RSF. It 
seemed that predictive modeling using tumor tissue metabolome based on RSF for OS in females 
and RFS for males was plausible with a minimum PER of 0.2100 and 0.2356, respectively 
(Table 3). To justify the model, it is necessary to follow a standard machine learning modeling 
process that split the data into a training set and testing set, and picked a trained model based on 
the training set and tested it on the testing set (Fig. 1). It is worth mentioning that the training set 
results might not be the same as results from the entire data set for 95 female CRC patients due 
to sampling randomness. Furthermore, a successful random split would not cause too extreme 
deviations between the two results. So far, this step was only meant to explore the possibility of 
making predictions for different prognostic outcomes and populations. We could make 
inferences using the results, but it would be better to test the findings in an independent data set. 
Since we only obtained one cohort data, the only way is to split it into two independent parts to 
for modeling, as Fig.1 described. We used a training set with 60% randomly selected patients to 
select features and test it in a test set consisting of the remaining 40% patients.  
For simplicity, in this thesis, we only further investigated models for OS for female patients with 
a lower prediction error rate of 0.21 using the RSF algorithm. The entire dataset was split into 
two independent groups, 60% for training and 40% for testing. There were no statistically 
significant differences among the features of the two groups (Table 4). Mann-Whitney U test for 
continuous variables; Chi-square test and Fisher’s exact test for categorical variables. The 
difference in survival outcome was absent between the two sets as well (Fig. 3) so that the death 
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events were balanced. Then it was safe to use the training set to generate a prediction model and 
employ the testing set to estimate the model’s accuracy.  
Cox proportional hazard regression (CPH) models with variable selection 
using forward stepwise and LASSO  
We built the first CPH model (COX1) with statistically significant metabolites in the individual 
analysis with clinical covariates from the training set: glutathione, glutathione disulfide, glycerol 
3-phosphate, phosphoenolpyruvate, succinate, UDP-D-Glucose (Table 5). Then we used forward 
selection methods to select a group of variables with the least AIC (Akaike information criterion) 
for CPH model (COX2) that included clinical stage, age, succinate, glycerol 3-phosphate, and 
glutathione (Table 5). Recurrence status was correlated with OS (Fisher's Exact Test: P < 0.001), 
but it should not be included in any of the models since this was observed simultaneously with 
OS in practice. For COX1, the C-index was 0.9494 (0.9043-0.9945) for training set and 0.6000 
(0.3656-0.8344) for testing set as shown in Table 7; for COX2, C-index was 0.9448 (0.8938-
0.9958) for training set and 0.6370 (0.4257-0.8483) for the testing set. However, both models 
violated the proportional hazard assumption, which might be due to nonlinear covariate 
relationships or lack of independence that made the results less reliable. These two models in 
Table 5 were only for illustration and reference; they were invalid for making predictions and 
interpretation because the violations of the proportional hazard assumption produced biased 
hazard ratios. 
The variable selection methods for both COX1 and COX2 were primitively conducted manually, 
and thus we turned to other methods suitable for addressing dimensionality reduction. Cox-
LASSO regression could use L1 penalty for feature selection and dimension reduction. Using 10-
fold cross-validation (C ), we tuned the λ parameter and selected the best one to produce a 
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selected set of variables. We trained the Cox-LASSO in our training set, as shown in Fig. 4, 
where the C-index peaked at 0.7173 when λ was around 0.1273 (Log λ = -2.06). When λ is very 
small, the LASSO produced results similar to a CPH model with all the coefficients included. As 
λ grew, the regularization term had a greater effect on penalizing more variable coefficients to 
zero, leaving fewer variables in the model. Finally, only variables that were influential enough 
were included in the model. The training process was summarized in Fig. 4. At Log(λ)= -2.06, 
only two variables had coefficients > 0:  Clinical stage (coefficient = 0.3486) and lysoPC (16:0) 
(coefficient = 0.2178), both of which were positive indicating their contribution to lower overall 
survival probabilities. We used this λ to test the prediction performance on the testing set, and we 
got a C-index of 0.6667. To obtain a mean and 95% CI for the C-index for the training set and 
testing set, we ran the model 1000 times, and the C-index was 0.7056 (0.6903-0.7210) for the 
training set and 0.6440 (0.6321-0.6558) for the testing set as shown in Table 7.  
Random survival forest (RSF) model  
We first used the stepwise RSF backward algorithm by selecting a group of variables that 
produced the best prediction performance using the training set. The model (RSF1) included 
asparagine, citrulline, glutathione, lysoPC (16:0), phosphoenolpyruvate together with forcibly 
included covariates (tumor stage, clinical location, age, and chemotherapy history), and the 
prediction error rate reaches a minimum of 0.1883 (C-index=0.8117). Then we built an RSF 
model (RSF2) including variables with relative variable importance (VIMP) > 5% (RSF1) for 
both females: clinical stage, citrulline, chemotherapy history, age, hypoxanthine, glycerol 3-
phosphate, glutathione, asparagine, DHAPorG3P, and spermine (Table 6, Fig. 6). We ran the 
models 1000 times to obtain their mean and 95% CI. RSF1 had a high C-index in the training set 
of 0.8117 (95% CI: 0.8104-0.8131) and a lower C-index for the testing set 0.7765 (95% CI: 
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0.7756-0.7773). RSF2 had a high C-index in the training set of 0.8469 (95% CI: 0.8462-0.8476), 
but its C-index for the testing set is much lower (0.6589, 95% CI: 0.6578-0.6600). 
The associations between the nine most predictive variables by RSF1 and OS are demonstrated 
in Fig. 5. The estimated partial survival for a covariate indicates estimated survival for different 
levels of the covariate after accounting for the average effects of the other selected metabolites 
and the covariates. It can be seen from Figure 5, in continuous risk factor for example, as the 
asparagine abundance increased up to about 4000, the 5-year predicted overall survival 
probability decreases slowly from 95% to 90%, and then it decreased at a sharper rate until reach 
65% (Fig. 5A), and a similar trend was found in citrulline (Fig. 5B). Glutathione, lysoPC (16:0) 
and phosphoenolpyruvate had nonlinear relationships between predicted survival probability 
their abundances with several turning points in their plots. For categorical variables such as 
anatomic tumor location, right-sided cancer (RCC) demonstrated a lower 5-year predicted 
survival estimated at around 5% compared with LCC on average (Fig. 5I), which agreed with 
many previous findings2930. Female patients with chemotherapy history or at the late clinical 
stage had about a 5% lower probability of survival. As Fig. 5J shows, the prediction error rates 
decreased drastically and became stable and stayed around 0.18 as the number of trees grew to 
1000. It is worth mentioning that calculation methods for these partial survival plots were not the 
same as Kaplan–Meier curve or CPH models, and RSF models do not have to observe the 
proportional hazard assumption.  
Logistic regression model (LR) 
Logistic regression (LR) was not the same as other methods that treated the data as time-to-event 
data. Instead, it neglected the survival time and coded the death event as a binary variable 
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(survival = 0, death = 1). The methods simplified the question into predicting “whether the 
patient would die or not within the 5-year interval” without considering when the death would 
occur. The predictive performance in the training set was better than the testing set, which 
indicated a typical overfitting problem within the LR method (Fig. 7): LR had good specificity 
(0.875) but inferior sensitivity (0.200). High specificity demonstrated this method had a strong 
ability to correctly designate an individual who would not die in 5 years as a survivor, which 
would help avoid unnecessary financial costs or mental burden for CRC patients. Low sensitivity 
corresponded to more false-negative results, and thus more events of death within 5-years would 
be not be anticipated, resulting in losing opportunities for early preventive intervention for CRC 
female patients. The low sensitivity made its AUC (area under the curve) for the testing set 
relatively low with a lower bound below 0.5. As a result, this method should be improved before 
being used in clinical practice. 
Comparing predictive performance for the models 
The performances of these five models were evaluated based on C-index (1-prediction error 
rate). A C-index larger than 0.75 is desired and indicates a good model. C-index < 0.5 indicates a 
poor performance meaning that the model is no better than predicting an outcome than random 
chance. 95% CI that includes 0.5 is considered to be not significant. For RSF1, RSF2, and Cox-
LASSO, 95% CIs were calculated by running the models in the testing set 1000 times. COX1 
and COX2 fit the training data well with less error rate than other methods. However, their 
predictive abilities in the testing set were not satisfying, with a lower bound of 95% CI below 0.5 
(Table 7). Again, COX1 and COX2 were invalid and were just for comparison because of biased 
hazard ratios due to violations of the proportional hazard assumption. RSF1 model outperformed 
in predicting female 5-year OS with two stable and relatively high C-indexes of 0.8117 (95% CI: 
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0.8104-0.8131) and 0.7765 (95% CI: 0.7756-0.7773) for the training set and the testing set, 
respectively; both were above the acceptance threshold of 0.75. Results show an overfitting 
problem with RSF2 as its performance in the training set (C-index = 0.8469, 95% CI: 0.8462-
0.8476) was good, while its prediction error in the testing set was huge (nearly 0.34). Cox-
LASSO had problems of underfitting with the lowest C-index for the training set among the six 
models (C-index = 0.7056, 95% CI: 0.6903-0.7210), though the performance was more stable 
than LR. For future clinical practice purposes, RSF1 has the potential to be accepted if updated 
using other established clinical and biological variables combined with other screening 
measurements. Other models suffered from either underfitting or overfitting with a lack of 
robustness in the testing set.     
The prediction performances over time of COX1, COX2, RSF1 and RSF2 were examined as 
shown in Fig. 8. The predictive abilities of the four models in the testing set were examined over 
time (the testing set did not have a death event before month 20). All four models showed better 
predictive abilities at a later time. RSF1 had a stably good prediction performance since month 
30 in general. C-index of RSF1 during month 30 to month 40 hit 0.75, then dropped a little bit 
before month 53, and soon reached above 0.75, indicating a promising possibility of predicting 








This study is the first cohort using untargeted metabolomics to investigate possible associations 
between 91 tumor tissue metabolites and colorectal cancer prognosis. Our analyses on individual 
metabolites identified 11 metabolites with sex interactions in the associations with colorectal 
cancer 5-year overall survival (OS) and five metabolites for 5-year recurrence-free survival 
(RFS), among which asparagine was observed to have sex dimorphisms for both OS and RFS. 
These findings suggest that different metabolism by sex were associated with different CRC 
prognostic outcomes, and it was vital to build targeted predictive models by sex from the point of 
view of precision medicine. By applying an RSF backward selection procedure within the 
training set for female CRC patients (n = 58), five metabolites were identified to be most 
predictive for the 5-year OS: glutathione, citrulline, phosphoenolpyruvate, lysoPC (16:0), and 
asparagine. As demonstrated by the RSF1 model that incorporated these five metabolites might 
provide new insights to the prediction of colorectal cancer 5-year OS for female patients when 
used together with known epidemiological risk factors of CRC (clinical stage, chemotherapy 
history, anatomic tumor location, and age). The comparison of the C-index (1- prediction error 
rate) of five other different models revealed that especially noise metabolites were removed by 
the RSF backward selection process, resulting in identifying the most predictive metabolites. In 
contrast, RSF2 that included relative variable importance > 20% showed a better fitting 
performance in the training set than RSF1, but it could not achieve a comparable C-index in the 
testing set, which suggested its poor generalizability due to overfitting. Moreover, the 
visualization by partial plots revealed nonlinear associations between the abundance of identified 




Our exploratory analyses and modeling indicated that traditional hazards-based models such as 
CPH were not designed for prediction but to infer variables’ impact on a prognostic outcome21, 
and were too primitive for high-dimensional metabolomics data. Instead, machine learning 
algorithms performed better in predicting prognosis when we faced nonlinear interactions that 
were presented in Fig. 5, which would violate the linear proportional hazards condition (Table 
5). For example, Fig.5 I showed that RSF successfully distinguished the difference in 5-year 
predicted survival between right-sided cancer (RCC) and left-sided cancer (LCC), which might 
be hidden under the complex interactions between anatomic tumor location and tumor tissue 
metabolites. As expected, none of the CPH models discovered the location-specific difference, as 
CPH could not handle intricate inner interactions between metabolites and clinical variables so 
explicitly. A similar modeling process to model nonlinear gene interactions made comparisons 
between CPH and other machine learning methods, including RSF, which also proved the 
applicability of automatically assessing nonlinear effects and complex interactions by RSF21. 
These data-driven machine learning algorithms are unaffected to problems due to their natures 
that perform robust feature selection against multicollinearity internally. As a result, collinearity 
between variables did not impair the predictive accuracy and satisfied our goal of disengaging 
from multicollinearity problems21. In our study, RSF has also shown its ability to outperform 
classic CPH regressions at any time within the 5-year follow-up. As can be seen in Table 7, the 
two CPH models COX1 and COX2, had very high C-index in the training set, while they failed 
to handle the testing set. RSF1 using the backward selection algorithm showed the best 
performance, with the C-index of the training and testing sets reaching 0.812 and 0.777, 
respectively. The performance of RSF1 kept at a steady high C-index over time since month 20.  
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Interestingly, the variables with coefficients larger than 0 in the Cox-LASSO model were lysoPC 
(16:0) and clinical stage, which were also selected as predictors in RSF1 and RSF2, while COX1 
and COX2 did not include the lysoPC (16:0) metabolite. LysoPC (16:0) had a significant sex 
difference in overall survival in the individual metabolite analysis and was a risk factor for 
female OS (HROS=1.54 per SD, 95% CI: 1.04 - 2.27, P = 0.031). Cai et al. found that the 
lysophospholipids lysophosphatidylcholine were upregulated in women with RCC (stage I) but 
not in men, suggesting that the higher levels of lysophospholipids in women with RCC would 
promote fatty acid supply15 that was essential for cancer cell growth31. These findings justified 
our findings identifying lysoPC (16:0) as an important predictor for CRC prognosis for females. 
We also found that asparagine was an essential metabolite for female prognosis. Asparagine had 
sex interactions with both OS and RFS and was tested to be an important predictor in both RSF1 
and RSF2 models. Asparagine (Asn) abundance was associated with lower probabilities of 
overall survival, which agreed with the previous finding of female survival and asparagine 
synthetase (ASNS) expression15. Johnson Lab found that asparagine increased threonine uptake in 
females RCCS that were nutrient deplete and could lead to aggressive phenotypes in those 
patients15. In Fig.2, asparagine and threonine were all not significantly associated with OS for 
female patients but were both associated with better OS for males. In cancer research based on in 
vitro experiments, ASNS catalyzed asparagine was crucial for cancer cell growth by promoting 
cancer cell amino acid homeostasis, anabolic metabolism, proliferation32, and Asn availability in 
vitro strongly interplayed the metastatic progression of breast cancer33. For CRC specifically, 
SOX12 expression promoted colorectal cancer cell proliferation and metastasis and facilitated 
ASNS expression34. Another frequently found mutation in the KRAS gene in colorectal cancer35 
was observed with a marked decrease in aspartate level and increased asparagine level by an 
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upregulated ASNS expression, which indicated that ASNS might be a novel therapeutic target for 
KRAS-mutant CRC 36. Moreover, SLC25A22 served as an essential metabolic regulator for CRC 
progression by promoting the synthesis of aspartate-derived amino acids (asparagine) in KRAS-
mutant CRC cells37. Knott et al. reported that increased dietary asparagine in animals promotes 
metastatic progression in breast cancer, and dietary asparagine restriction inhibits metastasis 
without affecting the primary tumor growth38. The study drew great attention from academics 
and the media worldwide in 2018, ranked the 97th percentile (ranked 24th) of the 896 tracked 
articles of a similar age in Nature on Altmetric39. According to BBC News, researchers from 
Cambridge University claimed that patients with specific cancers might have developed an 
addiction to specific components of diets, and it may be necessary to modify a patient’s diet or 
change the way tumor cells get access to those nutrients with potential risks using drugs40. 
Consequently, both internally produced asparagine and external exposure to asparagine may 
influence CRC tumor progression. These studies provided strong evidence to support our 
identification of asparagine as a predictive risk factor of OS for female CRC patients. 
Besides, application of RSF with backward selection for all 95 female patients revealed that 
creatinine was a predictive factor for 5-year OS. Creatinine was found to be a valid variable for 
predicting CRC cases41 and was also reported with correlations to colon cancer based on other 
studies of urine42 and serum43 samples from colon cancer patients. Also, creatinine is a measure 
of cachexia, a syndrome characterized by unintentional weight loss44. The female patients we 
studied were all over 55 years old (with an average age of 71), which might allow us to identify 
creatinine as a predictive metabolite. However, whether creatinine has predictive ability among 
other age groups requires further investigations. 
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Some of the metabolites we observed might have multiple uses and are not just used by the 
cancer cells, such as polyamine, which could be used by both colon cancer cells and bacterial 
cells to build biofilms in colon adenomas/carcinomas45. Among the identified metabolites, 
asparagine utilization could be regulated by L-glutamine via gut microbiota46. Hence if the 
environmental milieu of the colon or rectum differs between males and females, it could 
determine how metabolites are used and thus affect cancer progression.  
Admittedly, because of the heterogeneity of different metabolomics data, there is no panacea 
model for predicting CRC based on any types of metabolomics data. The flowchart in Fig. 1 
illustrates a flexible, dynamic path for disease-related metabolomics research discovery. An 
increasing number of biomedical studies utilizing Automated Machine Learning (AutoML) 
methods have been applied to diseases such as cancer47, Alzheimer’s disease48, and 
cardiovascular diseases49, which leveraged advances in hyperparameter search and model 
selection based on metabolomics. Those studies used greater numbers of machine learning 
algorithms and selected the optimal ones that suit their data best. Therefore, chances are that the 
best model we built might not be the optimal one for our data, though random forest-based 
models tend to be more stable than the simple decision tree model. Nevertheless, this study could 
offer some insights into using metabolome to predicting CRC prognosis accounting for sex 
differences for future studies. 
The strength of this study is the application of untargeted metabolomics for CRC tumor tissue in 
a well-described population-based retrospective cohort with strictly standardized study protocols 
and a decades-long follow-up time. Tumor tissue metabolites have advantages over biomarkers 
extracted from blood and urine samples because tumor tissues directly reflect tumor 
microenvironment and metabolism, whereas components of other biofluids are liable to external 
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environmental interactions such as dietary intake. Also, tumor tissue samples are easier to store 
and more reliable for evaluating and predicting long-term prognosis than plasma samples that 
tend to degrade in hours or days50. In addition, Cai et al. discovered that CRC tumor tissue 
metabolites also differed by anatomic tumor location, and females with RCC were at higher risks 
of poor overall survival15, implying that studying sex differences in prognosis should include 
tumor location. Hence tumor tissue metabolic profiling considering tumor location was the 
optimum approach.  
Nonetheless, we should also admit the huge gap between real-world medical practice and 
bioinformatics studies due to low reproducibility, even some of which claimed to provide robust 
models. Evaluation of 184 studies on new prognostic markers of outcomes in acute pancreatitis 
showed that only 15% had a sample size > 100 patients, and < 40% reported information about 
patient recruitment, and none had power calculations51. Lack of replication efforts, small sample 
sizes, insufficient subsequent external validation, unclear evaluation criteria were the major 
causes of the failures in cancer biomarker discovery and translation along the biomarker 
pipeline525354. There is still a long way to go before our findings are applied to actual medical 
practice for colorectal cancer, such as providing risk scores by measuring tumor tissue metabolic 
profile. Despite these possible defects and obstacles, this study could provide hints about 
predictive prognostic biomarkers for colorectal cancer from the perspectives of sex difference 







We identified five predictive metabolites for female CRC patients that could be used to predict 
5-year overall survival using the random survival forest (RSF) backward selection algorithm. We 
concluded that the RSF prediction method based on the backward selection algorithm was 
promising in predicting 5-year overall survival (OS) for female CRC patients. The results could 
also justify the urgent need for personalized CRC screening programs by sex or other factors 
which benefit a targeted group of the population at higher risks with optimal resource allocation. 
Due to a large number of correlated variables that brought problems of multiple comparison, 
insufficient statistical power, and higher risks of multicollinearity, false-positive detection with 
significant P values by chance are sometimes unavoidable in exploratory data analysis of 
complex metabolomic data based on traditional statistical regression approaches. Moreover, most 
metabolites identified with sex differences in CRC prognosis had insignificant P values after 
FDR adjustment., which need future replication studies to confirm their associations with CRC 
prognosis and sex differences. Fortunately, we were able to take advantage of bootstrapping and 
the interruption of intercorrelation structures by random node splitting to reduce overfitting, 
multicollinearity, and select reliable predictive variables using RSF. Furthermore, nonlinear 
relationships between the identified metabolites and predicted survival time could be visualized 
to determine potential clinical thresholds after validated in further population studies.  
The predictive performance of this method in the training set was satisfactory (C-index = 0.81), 
and the prediction accuracy in the testing set was slightly lower but still acceptable (C-index = 
0.78). The model is reliable in the statistic aspect but may need further improvement in clinical 
practice that requires much higher accuracy. Several limitations might lead to these results: 1) a 
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small sample size with limited death event for data mining could only provide limited 
information; 2) established covariates for predicting CRC development and poor prognosis were 
absent in our data set, such as genotype, family history, metastasis, BMI, dietary factors, alcohol 
consumption, smoking behaviors; 3) incomplete information of the treatment or drug history 
within the follow-up period. The already good predictive accuracy in the testing set laid the 
foundation for improving the prediction performance after adding more variables mentioned 
above using a larger cohort. Moreover, it is also helpful to conduct a multi-omics analysis that is 
more comprehensive than metabolomics alone. Afterward, several external validation processes 
using independent cohort data are necessary before being applied to clinical practice. We foresee 
the enormous potential of using novel biomarkers to predict prognosis by multi-omics 
approaches based on machine learning, statistical learning methods.  
Ultimately, my recommendations for the YSPH MPH program would be to set up new courses 
focusing on biomarker discovery for cancer epidemiology (both methodology, data analysis, and 
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Supplementary Table 1. Demographic characteristics and clinical factors for each subgroup. RCC = right-sided colon cancer, LCC = left-sided colon cancer. 
Subgroup  














Males 10  15  23  25  15  14  
Females 12  10  21  17  17  18  
Age, mean (SD) 
Males  73.9 (6.5) 69.3 (5.8) 72.9 (7.8) 72.2 (8.5) 73.5 (7.8) 63.7 (5.8) 
Females 72.1 (6.2) 69.6 (7.6) 73.5 (9.8) 69.1 (7.8) 72.2 (6.6) 71.1 (6.0) 
5-year Overall survival rate, %a  
Males 87.5 85.1 76.5 74.1 47.1 78.6 
Females 100 100 82.9 100 65.2 61.8 
5-year Recurrence-free survival rate, %a 
Males 90.0 78.3 86.8 67.6 82.1 70.1 
Females 90.9 100.0 87.5 87.4 76.0 68.8 


















Supplementary Table 2. Prognosis among different subgroups of patients after combining stage I and II together to allow analysis of Anatomic location: RCC 
vs. LCC females  
5-year Overall Survival (OS) 
Subgroup RCC males RCC females LCC males LCC females 
Eventc 0 1 0 1 0 1 0 1 
Stage aa 28 5 30 3 32 8 27 0 
Stage bb 8 7 12 5 11 3 12 6 
Total 36 12 42 8 43 11 39 6 
5-year Recurrence-free Survival (RFS) 
Subgroup  RCC males RCC females LCC males LCC females 
Eventd 0 1 0 1 0 1 0 1 
Stage aa 30 3 30 3 32 8 25 2 
Stage bb 13 2 14 3 10 4 13 5 
Total 43 5 44 6 42 12 38 7 
 
a Stage a combines Stage I and II together which refers to earlier stages. 
b Stage b refers to Stage III.  
c Event = death. 1= the event occurred within 5 years of follow-up, 0 = the event did not occur within 5 years of follow-up (survived or censored). 
d Event = recurrence. 1= recurrence occurred within 5 years of follow-up, 0 = recurrence does not occur within 5 years of follow-up. If a patient died before CRC 
recurrence, it will be counted towards a death event. 
 
Notes: 
If a patient died for any reason without recurrence within follow-up time (no more than 5 years), it was only counted toward a death event in OS.  
If a patient experienced recurrence but did not die within follow-up time (no more than 5 years), it was only counted toward a recurrence event in RFS. 
If a patient experienced recurrence and then died within follow-up time (no more than 5 years), it was counted toward a recurrence event in RFS and a death 
event in OS.  
If a patient experienced neither recurrence nor death within follow-up time (no more than 5 years), the event was 0 for both OS and RFS. 
Due to the absence of death events among females at clinical stage I, we regarded stage I and II patients as “stage a” (early stage) and stage III patients as “stage 










Supplementary Table 3. Associations between individual metabolites and 5-year overall survival (OS) by sex, adjusted for anatomic location, clinical stages, 
and age).   
Metabolite name 
Females Males 
Int. Sex P value * 
HR 95% CI P valuea HR 95% CI P valuea 
Acetyl-lysine 0.96 0.74 - 1.25 0.786 0.83 0.72 - 0.96 0.012 0.342 
Adenosine 0.91 0.70 - 1.19 0.507 1.29 1.03 - 1.62 0.026 0.044 
Alanine 1.05 0.77 - 1.42 0.762 0.77 0.61 - 0.98 0.034 0.096 
Argininosuccinic acid 0.93 0.71 - 1.23 0.613 0.74 0.58 - 0.93 0.010 0.154 
Asparagine 1.45 0.87 - 2.42 0.154 0.72 0.55 - 0.96 0.025 0.029 
Carnitine 0.62 0.04 - 9.47 0.733 0.56 0.34 - 0.93 0.026 0.881 
Citrulline 1.66 0.98 - 2.81 0.061 0.65 0.46 - 0.92 0.014 0.002 
Glycerol 3-phosphate 3.64 1.30 - 10.2 0.014 0.91 0.47 - 1.77 0.777 0.017 
Hypoxanthine 1.04 0.35 - 3.13 0.943 0.65 0.44 - 0.95 0.027 0.444 
LysoPC(16:0) 1.54 1.04 - 2.27 0.031 0.85 0.66 - 1.11 0.244 0.008 
Ornithine 0.96 0.56 - 1.66 0.895 0.68 0.47 - 0.97 0.035 0.316 
Serine 1.24 0.65 - 2.38 0.519 0.55 0.37 - 0.81 0.002 0.035 
Spermine 1.40 1.01 - 1.93 0.041 1.03 0.83 - 1.27 0.813 0.086 
Succinate 0.34 0.12 - 0.96 0.042 1.77 1.21 - 2.58 0.003 0.004 
Threonine 1.11 0.67 - 1.86 0.685 0.61 0.44 - 0.85 0.004 0.035 
UDP-D-Glucose 0.81 0.67 - 0.97 0.023 1.15 0.95 - 1.40 0.161 0.012 
Uracil 1.21 0.54 - 2.69 0.643 0.44 0.28 - 0.70 0.001 0.024 
Xanthosine 1.21 0.86 - 1.71 0.283 0.71 0.54 - 0.94 0.016 0.027 
a Raw P value before FDR adjustment. *Each metabolite with sex-interaction P value. The abundance of each metabolite was treated as a continuous variable and 











Supplementary Table 4. Associations between individual metabolites and 5-year recurrence-free survival (RFS) by sex, adjusted for anatomic location, clinical 
stages, and age).   
Metabolite name 
Females Males 
Int. Sex P value * 
HR 95% CI P valuea HR 95% CI P valuea 
Acetyl-lysine 0.97 0.75 - 1.25 0.795 0.79 0.68 - 0.93 0.003 0.102 
Alanine 1.09 0.79 - 1.51 0.607 0.75 0.59 - 0.95 0.017 0.070 
AMP 1.1 0.68 - 1.78 0.699 0.71 0.53 - 0.95 0.019 0.113 
Argininosuccinic acid 1.02 0.77 - 1.34 0.906 0.71 0.54 - 0.93 0.012 0.041 
Asparagine 1.45 0.91 - 2.32 0.119 0.74 0.56 - 0.98 0.039 0.009 
Carnitine 3.23 0.23 - 44.44 0.382 0.38 0.23 - 0.65 <0.001 0.115 
CMP 0.97 0.56 - 1.67 0.908 0.70 0.51 - 0.96 0.028 0.278 
Creatinine 0.72 0.41 - 1.26 0.251 1.63 1.13 - 2.36 0.009 0.033 
Cytidine 0.56 0.34 - 0.9 0.017 0.75 0.49 - 1.15 0.185 0.246 
Fructose 6-phosphate 0.82 0.53 - 1.26 0.355 0.68 0.49 - 0.95 0.025 0.556 
Glutathione 0.74 0.57 - 0.95 0.018 0.92 0.80 - 1.06 0.236 0.104 
Glutathione disulfide 0.73 0.58 - 0.91 0.006 0.82 0.68 - 0.99 0.037 0.329 
GMP 1.05 0.69 - 1.61 0.818 0.74 0.57 - 0.96 0.024 0.157 
Hypoxanthine 1.87 0.57 - 6.19 0.304 0.32 0.21 - 0.51 <0.001 0.009 
LysoPC(16:1) 1.05 0.75 - 1.47 0.765 0.77 0.61 - 0.96 0.023 0.100 
LysoPE(18:1) 0.98 0.73 - 1.31 0.897 0.83 0.69 – 1.00 0.049 0.294 
LysoPE(20:1) 0.97 0.77 - 1.23 0.812 0.84 0.71 - 0.98 0.028 0.218 
LysoPE(22:5) 1.08 0.70 - 1.67 0.721 0.70 0.53 - 0.91 0.009 0.070 
LysoPE(18:2) 1.07 0.70 - 1.63 0.767 0.73 0.55 - 0.95 0.021 0.119 
Serine 1.39 0.72 - 2.69 0.329 0.59 0.41 - 0.85 0.005 0.013 
Sphinganine-1-phosphate 0.92 0.59 - 1.44 0.715 0.67 0.48 - 0.94 0.022 0.206 
Stearamide 0.91 0.62 - 1.33 0.629 0.70 0.53 - 0.92 0.011 0.206 
Threonine 0.96 0.58 - 1.60 0.885 0.65 0.47 - 0.90 0.009 0.086 
Xanthine 0.59 0.36 - 0.98 0.043 0.69 0.49 - 0.98 0.036 0.869 
Xanthosine 1.01 0.73 - 1.38 0.972 0.72 0.52 - 0.99 0.044 0.112 
a Raw P value before FDR adjustment. *Each metabolite with sex-interaction P value. The abundance of each metabolite was treated as a continuous variable and 





Principal Component Analysis results for females and males 
 
Supplementary Figure 1. Results of 
Principal Component Analysis (PCA) by 
sex. Screen plot for females (A) and for 
males (B) illustrated the explained 
variance by top 10 components. PCA 
biplot for females (C) and males (D) 
indicated a poor overall survival (OS) 
classification ability by considering the 
first two components based on metabolite 
abundance. Amino acids (e.g., threonine, 
alanine, serine, and asparagine etc.) were 
successfully distinguished and clustered 
around at the positive direction of 
dimension 2 for both females (C) and 



























Supplementary Table 5. Eigenvalue and variance of components retained for females and males. We only analyzed components with an eigenvalue greater than 
1 based on the Kaiser rule1. For females, 19 dimensions were adopted in further analysis, which accounted for 83.23% of the total variance. For males, 20 
dimensions were included with a cumulative variance of 83.70%. 
 Females Males 
Eigenvalue Variance percent Cumulative variance percent Eigenvalue Variance percent Cumulative variance percent 
Dim.1 18.93 20.81 20.81 17.45 19.18 19.18 
Dim.2 15.59 17.13 37.94 14.37 15.79 34.96 
Dim.3 9.39 10.32 48.26 9.44 10.38 45.34 
Dim.4 4.23 4.65 52.91 4.08 4.49 49.83 
Dim.5 3.39 3.73 56.64 3.87 4.25 54.08 
Dim.6 3.10 3.41 60.05 3.07 3.38 57.46 
Dim.7 2.70 2.96 63.01 2.90 3.19 60.65 
Dim.8 2.25 2.47 65.48 2.57 2.82 63.47 
Dim.9 1.93 2.12 67.60 2.25 2.48 65.95 
Dim.10 1.89 2.08 69.67 2.12 2.33 68.28 
Dim.11 1.73 1.90 71.58 1.77 1.95 70.23 
Dim.12 1.68 1.85 73.43 1.69 1.86 72.08 
Dim.13 1.49 1.64 75.06 1.63 1.79 73.87 
Dim.14 1.41 1.55 76.62 1.52 1.67 75.54 
Dim.15 1.39 1.53 78.15 1.47 1.61 77.15 
Dim.16 1.29 1.41 79.56 1.42 1.56 78.72 
Dim.17 1.22 1.34 80.90 1.28 1.41 80.13 
Dim.18 1.11 1.22 82.12 1.16 1.27 81.40 
Dim.19 1.01 1.11 83.23 1.08 1.19 82.58 













1 KAISER, H. E (1960). The application of electronic computers to factor analysis. Education & Psychological Measurement, 20, 14I-151. 
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Supplementary Table 6. Statistically significant results using CPH analysis for individual top 19 components for females and top 20 components (with 
eigenvalues > 1) for males adjusted for clinical stage, tumor location, and age. No component was associated with OS for female patients. Component 5 and 19 
were associated with RSF among females. Metabolites noted with (+) were positively associated with the corresponding component, and the higher the absolute 
value of loading, the greater the relationship, vice versa. A component with HR > 1 was associated with an increased risk of poorer prognosis. E.g., component 5 
was associated with both poor OS and RSF for males. Males with higher levels of succinate, creatinine, L-phenylalanine, and lower levels of carnitine and 






(+): loading > 0.2; (-): loading <- 0.2 
HR (95% CI) P 
C-index 
(Se) 
Any variable Violated 
PH assumption 
OS (Females) None - - - - - 
OS (Males) 5 
Succinate (+), Creatinine (+), L-Phenylalanine (-), 
Carnitine (-), Cytidine (-) 






Palmitic acid (+), Diacetylspermine (+), Stearic acid (+), 
Oleic acid (+), Glutathione disulfide (-), Adenosine (-), 
Xanthine (-) 





Vitamin E (+), CMP, PC(36:2) (+), Lactate (+), D-
Glucuronate (+), Adenosine (+), 






Ribulose 5-phosphate (+), AMP (+), ADP-ribose (+), L-
Phenylalanine (-), Carnitine (-), Cytidine (-) 





Succinate (+), Creatinine (+), L-Phenylalanine (-), 
Carnitine (-), Cytidine (-) 
1.34 (1.13-1.59) 0.001 
0.706 
(0.07) 
Yes 
 
 
 
 
 
 
 
